The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !
Wednesday, August 10, 2022
Tuesday, August 9, 2022
Volta Media™ Network Surpasses One Billion Monthly Impressions and More Than 30,000 Tons of CO2 Emissions Avoided
Volta attracts larger digital media budgets with expanded measurement, programmatic buying, and data-driven targeting capabilities for advertisers
SAN FRANCISCO--(BUSINESS WIRE)-- Volta
Tuesday, July 26, 2022
Monday, July 25, 2022
Sunday, July 24, 2022
Thursday, July 21, 2022
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
sAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189
Wednesday, July 20, 2022
Tuesday, July 19, 2022
Subscribe to:
Posts (Atom)